Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
LUNELLE is a combined hormonal contraceptive containing estradiol cypionate and medroxyprogesterone acetate, administered as a monthly intramuscular injection. It prevents pregnancy by suppressing ovulation and altering the cervical mucus and endometrium. This product was voluntarily withdrawn from the U.S. market in 2002 despite FDA approval, due to manufacturing and safety concerns.
Product is in late-stage lifecycle with minimal current market presence; career opportunities are limited and primarily historical in nature.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
LUNELLE offers no current career opportunities as a discontinued product. Historical involvement would be limited to pharmaceutical archival roles or contraceptive market analysts studying product failures and market dynamics. Career growth and advancement would require transition to active product portfolios within the women's health or contraceptive space.
Worked on LUNELLE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo